Thinking rare disease (insurance) pool - all care from single payer life long - value for GT will appreciate over time in savings to the whole pool. #ASTCTChat@Eddie_Cliff@foglesong_md
#ASTCTChat Q2: What alternative payment models could be employed to pay for high cost, and curative therapies? How can we balance cost to payer against benefit to patients and society? https://t.co/9eOIHuWfzm
I think it will have to be - alloBMT will continue to look cheaper and cheaper by comparison - $2.8M just for GT thalassemia product itself #ASTCTChat.
State level advocacy is critical to ensuring/expanding coverage under Medicaid - 55% of patients with #SickleCell are covered by Medicaid - coverage for coming #GeneTherapy will happen state-by-state
Medicare coverage for otherwise excluded indications has made a difference in expanding access #MultipleMyeloma and #Myelodysplasia#ASTCTChat https://t.co/1POPJv02Ar
What’s enough to drag me back out to twitterverse? Why, hosting a #ASTCTChat for the Value and Healthcare Economics SIG - join the convo on https://t.co/PdXLs0AEDf @ASTCT
#ASTCTChat Q1: How does your institution address the needs of a caregiver and family support for patients undergoing transplantation? https://t.co/9eOIHuWfzm
Excited to join @BrightLightFilm and #BAAFF to screen The Farewell - stay for our panel discussion with oncologists and community members https://t.co/Xd6qQchxrd
Only 2 adult heart transplant centers in the U.S. with at least 100 patients transplanted over the past 2.5 years have seen better than 96% of their patients alive with a functioning new heart 1 year after transplant. We are proud to be 1 of those centers! https://t.co/oqFPuzcsSP